This document is a publication of a United States Patent Application (US20260078529A1) filed by inventors Lei DING and Lawrence S. LAMB, JR. The application describes novel γδ T-cells engineered to express a multivalent Chlorotoxin Chimeric Antigen Receptor (CLTX-CAR) along with a survival factor. It also covers pharmaceutical compositions and methods for treating cancer or tumors by administering these engineered T-cells, potentially in conjunction with a chemotherapeutic agent to which the survival factor confers resistance.

As this is a patent application publication, it does not impose immediate compliance obligations on regulated entities. However, it signals potential future developments in cancer therapeutics and immunotherapy. Companies involved in drug development, cell therapy, and oncology research should monitor this and related patent filings for insights into emerging technologies and potential intellectual property landscapes in the field.